(Total Views: 975)
Posted On: 08/15/2023 10:30:31 PM
Post# of 148894
(Edited)
I’m sure they all collaborate time to time but this is interesting article.
https://www.pharmaceutical-technology.com/com...mparisons/
MRK working with Moderna on cancer vaccines.
“Phase I clinical trials for pancreatic cancer and breast cancer are due to end in November and December 2023, respectively, and a large Phase I clinical study testing the efficacy of the vaccine against multiple cancers, such as bladder cancer, colorectal cancer, and head and neck cancer, is due to end in September 2023.“
Wait why does this sound so familiar!? I believe this was specifically mentioned during one of the CCs I can’t remember which one.
Read More: https://investorshangout.com/post/newpost/605...z8AVtnE8Lb
Alright I swear Dr Kelly stated this in his last CC I can’t find it but I forgot about the basket trial.
“Leronlimab solid tumour trial completed
CytoDyn’s leronlimab for CCR5+ locally advanced or metastatic solid tumours saw its PTSR increase in multiple cancer indications after its Phase II basket trial completed. The trial looked at 22 cancer types, and the largest PTSR changes occurred in glioblastoma multiforme (GBM), throat cancer, and bladder cancer. The PTSR leapt nine points to 32% in GBM, and four points to 37% in both throat and bladder cancer” Insert-tag-here
So did our basket trial lead to a phase 1 trial? Maybe the phase 2 data lead to a new trial a phase 1? I don’t know if that would have to be disclosed. We haven’t heard a word about the basket trial.
https://www.clinicaltrialsarena.com/features/...ompletion/
https://www.biospace.com/article/embattled-cy...h-tumors-/
To this end, Arman is actively working to bring in “industry entities who are qualified for their roles.”
Also key for Arman is to narrow the company’s clinical development focus.
Along with NASH, CytoDyn will focus primarily on oncology. Here, the company will target colorectal cancer and hormone receptor-positive, HER2-negative breast cancer.
These are both areas where checkpoint inhibitors have failed to show efficacy when added to a standard-of-care backbone, Arman said, adding that leronlimab has shown positive signals in both.
“From a mechanistic standpoint, we believe we could get a synergistic effect with a checkpoint inhibitor,” he said.
Leronlimab is currently being trialed in combination with Keytruda (pembrolizumab) in a breast cancer xenograft model in partnership with MD Anderson Cancer Center.
Arman said CytoDyn expects to observe an enhanced anti-tumor effect from the combination and identify immunological biomarkers.
In terms of future partnerships, Arman isn’t concerned that CytoDyn’s history will have a negative effect.
“I think that most companies are data-first,” he said. “If we come and we show the data that we have…I think they’ll see, here's an organization that has transformed from what it used to be.”
Read More: https://investorshangout.com/post/view?id=660...z8AVu7pgO7
It’s very interesting how that one article lines up with our basket trial, but it’s hard to say if it’s actually connected. Maybe someones can connect more dots. It almost seems as if these trials have already been done/completed. Or these trials aren’t related at all as I assume lost of companies do basket trials?
I’m sure they all collaborate time to time but this is interesting article.
https://www.pharmaceutical-technology.com/com...mparisons/
MRK working with Moderna on cancer vaccines.
“Phase I clinical trials for pancreatic cancer and breast cancer are due to end in November and December 2023, respectively, and a large Phase I clinical study testing the efficacy of the vaccine against multiple cancers, such as bladder cancer, colorectal cancer, and head and neck cancer, is due to end in September 2023.“
Wait why does this sound so familiar!? I believe this was specifically mentioned during one of the CCs I can’t remember which one.
Read More: https://investorshangout.com/post/newpost/605...z8AVtnE8Lb
Alright I swear Dr Kelly stated this in his last CC I can’t find it but I forgot about the basket trial.
“Leronlimab solid tumour trial completed
CytoDyn’s leronlimab for CCR5+ locally advanced or metastatic solid tumours saw its PTSR increase in multiple cancer indications after its Phase II basket trial completed. The trial looked at 22 cancer types, and the largest PTSR changes occurred in glioblastoma multiforme (GBM), throat cancer, and bladder cancer. The PTSR leapt nine points to 32% in GBM, and four points to 37% in both throat and bladder cancer” Insert-tag-here
So did our basket trial lead to a phase 1 trial? Maybe the phase 2 data lead to a new trial a phase 1? I don’t know if that would have to be disclosed. We haven’t heard a word about the basket trial.
https://www.clinicaltrialsarena.com/features/...ompletion/
https://www.biospace.com/article/embattled-cy...h-tumors-/
To this end, Arman is actively working to bring in “industry entities who are qualified for their roles.”
Also key for Arman is to narrow the company’s clinical development focus.
Along with NASH, CytoDyn will focus primarily on oncology. Here, the company will target colorectal cancer and hormone receptor-positive, HER2-negative breast cancer.
These are both areas where checkpoint inhibitors have failed to show efficacy when added to a standard-of-care backbone, Arman said, adding that leronlimab has shown positive signals in both.
“From a mechanistic standpoint, we believe we could get a synergistic effect with a checkpoint inhibitor,” he said.
Leronlimab is currently being trialed in combination with Keytruda (pembrolizumab) in a breast cancer xenograft model in partnership with MD Anderson Cancer Center.
Arman said CytoDyn expects to observe an enhanced anti-tumor effect from the combination and identify immunological biomarkers.
In terms of future partnerships, Arman isn’t concerned that CytoDyn’s history will have a negative effect.
“I think that most companies are data-first,” he said. “If we come and we show the data that we have…I think they’ll see, here's an organization that has transformed from what it used to be.”
Read More: https://investorshangout.com/post/view?id=660...z8AVu7pgO7
It’s very interesting how that one article lines up with our basket trial, but it’s hard to say if it’s actually connected. Maybe someones can connect more dots. It almost seems as if these trials have already been done/completed. Or these trials aren’t related at all as I assume lost of companies do basket trials?
(4)
(0)Scroll down for more posts ▼
